Neurophet, an artificial intelligence (AI) driven company specializing in brain disease diagnostics and treatment, announced on Tuesday its participation in the International Medical Imaging Technology Exhibition (ITEM 2026). The event is scheduled to take place in Yokohama, Japan, from April 17 to 19.
At ITEM 2026, Neurophet will partner with Hokuyaku Takeyama Holdings, a major Japanese medical device and pharmaceutical firm, to showcase their innovative software Neurophet Aqua AD. This cutting-edge technology is designed to monitor prescriptions, treatment efficacy, and potential side effects of dementia medications.
Neurophet Aqua AD is a sophisticated software that quantitatively analyzes magnetic resonance imaging (MRI) and positron emission tomography (PET) scans. It provides comprehensive brain imaging analysis capabilities crucial for administering anti-amyloid antibody therapies.
In addition to Neurophet Aqua AD, the company will present its neurodegeneration imaging analysis software, Neurophet Aqua, and PET image quantitative analysis tool, Neurophet Scale PET, at their exhibition booth.
Neurophet aims to leverage its partnership with Hokuyaku Takeyama Holdings, their local medical device distribution and sales partner, to identify potential clients in the Japanese market. This strategic collaboration is expected to expand Neurophet’s customer base and accelerate future sales initiatives in Japan.
Bin Jun-gil, co-Chief Executive Officer (CEO) of Neurophet, commented on the growing interest in Neurophet Aqua AD in Japan, where prescriptions for Alzheimer’s disease medications are on the rise. Its participation in ITEM 2026 will serve as a springboard to expand the product supply, with a focus on local medical institutions, he stated.